Dasatinib inhibits primary melanoma cell proliferation through morphology‑dependent disruption of Src‑ERK signaling

Wu,Jianghong; Liao,Xin; Yu,Bo; Su,Bing

doi:10.3892/ol.2012.1066

Dasatinib inhibits primary melanoma cell proliferation through morphology‑dependent disruption of Src‑ERK signaling

Authors:
- Jianghong Wu
- Xin Liao
- Bo Yu
- Bing Su
View Affiliations

Affiliations: Department of Gastric Cancer and Soft Tissue Sarcoma Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Biomedical Research Institute, Shenzhen-PKU-HKUST Medical Center, Futian, Shenzhen, Guangdong 518036, P.R. China, Department of Dermatology, Peking University Shenzhen Hospital, Futian, Shenzhen, Guangdong 518036, P.R. China
Published online on: December 10, 2012 https://doi.org/10.3892/ol.2012.1066
Pages: 527-532

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

New strategies for the treatment of advanced melanoma are urgently required. The RAS/RAF/MAPK pathway and c‑Src are deregulated in the majority of malignant melanomas, suggesting that they may interact functionally and are involved in the development and progression of the malignancy. Preclinical studies have demonstrated variable inhibition of melanoma cell growth by dasatinib in vitro. Src may act through different downstream signaling pathways. In the present study, we demonstrate that dasatinib induces changes in cell morphology, characterized by an arborized and contracted appearance, and accompanied by a reduction in cell proliferation in primary melanoma cells. This morphological change is demonstrated to be associated with the inhibition of nuclear translocation of activated ERK1/2. Together, these results indicate that Src may promote cell proliferation through the activation of the ERK signaling pathway in melanoma oncogenesis.

View Figures

View References

1.	Gogas HJ, Kirkwood JM and Sondak VK: Chemotherapy for metastatic melanoma: time for a change? Cancer. 109:455–464. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Frame MC: Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 117:989–998. 2004. View Article : Google Scholar : PubMed/NCBI
3.	Homsi J, Cubitt C and Daud A: The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 11:91–100. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL and Daud AI: Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 19:167–175. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM, Fairchild C, et al: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 47:6658–6661. 2004. View Article : Google Scholar
6.	Steinberg M: Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 29:2289–2308. 2007. View Article : Google Scholar
7.	Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O’Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP and Sawyers CL: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 354:2531–2541. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N and Slamon DJ: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative’ breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 105:319–326. 2007.PubMed/NCBI
9.	Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA and Corey SJ: Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 101:38–47. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Nautiyal J, Majumder P, Patel BB, Lee FY and Majumdar AP: Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. Cancer Lett. 283:143–151. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K and Nakagawa K: Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Nagaraj NS, Smith JJ, Revetta F, Washington MK and Merchant NB: Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 9:2322–2332. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Johnson FM, Saigal B, Talpaz M and Donato NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 11:6924–6932. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE and Corey SJ: Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res. 16:1149–1158. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Eustace AJ, Crown J, Clynes M and O’Donovan N: Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 6:532008. View Article : Google Scholar : PubMed/NCBI
16.	Buettner R, Mesa T, Vultur A, Lee F and Jove R: Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 6:1766–1774. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, Molinaro A and Sznol M: A phase 2 trial of dasatinib in advanced melanoma. Cancer. 117:2202–2208. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Goding CR: Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 14:1712–1728. 2000.PubMed/NCBI
19.	Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
20.	Maat W, el Filali M, Dirks-Mulder A, Luyten GP, Gruis NA, Desjardins L, Boender P, Jager MJ and van der Velden PA: Episodic Src activation in uveal melanoma revealed by kinase activity profiling. Br J Cancer. 101:312–319. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Busca R, Bertolotto C, Abbe P, Englaro W, Ishizaki T, Narumiya S, Boquet P, Ortonne JP and Ballotti R: Inhibition of Rho is required for cAMP-induced melanoma cell differentiation. Mol Biol Cell. 9:1367–1378. 1998. View Article : Google Scholar : PubMed/NCBI
22.	Folkman J and Moscona A: Role of cell shape in growth control. Nature. 273:345–349. 1978. View Article : Google Scholar : PubMed/NCBI
23.	Aplin AE and Juliano RL: Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J Cell Sci. 112:695–706. 1999.PubMed/NCBI
24.	Schmid-Alliana A, Menou L, Manie S, Schmid-Antomarchi H, Millet MA, Giuriato S, Ferrua B and Rossi B: Microtubule integrity regulates src-like and extracellular signal-regulated kinase activities in human pro-monocytic cells. Importance for interleukin-1 production. J Biol Chem. 273:3394–3400. 1998. View Article : Google Scholar
25.	Irigoyen JP, Besser D and Nagamine Y: Cytoskeleton reorganization induces the urokinase-type plasminogen activator gene via the Ras/extracellular signal-regulated kinase (ERK) signaling pathway. J Biol Chem. 272:1904–1909. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Rijken PJ, van Hal GJ, van der Heyden MA, Verkleij AJ and Boonstra J: Actin polymerization is required for negative feedback regulation of epidermal growth factor-induced signal transduction. Exp Cell Res. 243:254–262. 1998. View Article : Google Scholar : PubMed/NCBI
27.	Brunet A, Roux D, Lenormand P, Dowd S, Keyse S and Pouyssegur J: Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18:664–674. 1999. View Article : Google Scholar : PubMed/NCBI
28.	Alesiani D, Cicconi R, Mattei M, Bei R and Canini A: Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells. Int J Oncol. 34:1727–1735. 2009.PubMed/NCBI
29.	Samarakoon R and Higgins PJ: Pp60c-src mediates ERK activation/nuclear localization and PAI-1 gene expression in response to cellular deformation. J Cell Physiol. 195:411–420. 2003. View Article : Google Scholar : PubMed/NCBI
30.	Riley D, Carragher NO, Frame MC and Wyke JA: The mechanism of cell cycle regulation by v-Src. Oncogene. 20:5941–5950. 2001. View Article : Google Scholar : PubMed/NCBI
31.	Carothers Carraway CA, Fang H, Ye XH, Juang SH, Liu YC, Carvajal ME and Carraway KL: Membrane-microfilament interactions in ascites tumor cell microvilli. Identification and isolation of a large microfilament-associated membrane glycoprotein complex. J Biol Chem. 266:16238–16246. 1991.
32.	Carraway CA, Carvajal ME and Carraway KL: Association of the Ras to mitogen-activated protein kinase signal transduction pathway with microfilaments. Evidence for a p185(neu)-containing cell surface signal transduction particle linking the mitogenic pathway to a membrane-microfilament association site. J Biol Chem. 274:25659–25667. 1999.
33.	Fincham VJ, Chudleigh A and Frame MC: Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal disruption during transformation. J Cell Sci. 112:947–956. 1999.PubMed/NCBI
34.	Smith ER, Smedberg JL, Rula ME, Hamilton TC and Xu XX: Disassociation of MAPK activation and c-Fos expression in F9 embryonic carcinoma cells following retinoic acid-induced endoderm differentiation. J Biol Chem. 276:32094–32100. 2001. View Article : Google Scholar : PubMed/NCBI
35.	Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, Perrotta S, Della RF and Oliva A: The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One. 6:e285552011. View Article : Google Scholar
36.	Mazharian A, Ghevaert C, Zhang L, Massberg S and Watson SP: Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood. 117:5198–5206. 2011. View Article : Google Scholar : PubMed/NCBI